AKUMS
DRUGS & PHARMACEUTICALS LTD.
Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).
+91-11-69041000 CIN: L24239DL2004PLC125888
www.akums.in
akumsho@akums.net
+91-11-27023256

Ref: Akums/Exchange/2026-27/58 November 02, 2026

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Symbol: AKUMS

To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Mumbai – 400 001

Scrip Code: 544222

Sub: Outcome of the Board Meeting held on November 02, 2026

Respected Sir/Ma'am,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 **("SEBI LODR Regulations")**, this is to inform you that Board of Directors of Akums Drugs and Pharmaceuticals Limited **("the Company")** at its meeting held today i.e. Monday, November 02, 2026, has inter-alia considered and approved the followings:

1. Unaudited (Standalone & Consolidated) Financial Results of the Company for the quarter and half year ended on September 30, 2026:

   The Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter and half year ended on September 30, 2026, along with the Limited Review Reports thereon, as received from the Statutory Auditors, Walker Chandiok & Co. LLP, Chartered Accountants. Copies of the un-audited financial results (Standalone & Consolidated) along with the Limited Review Reports thereon are enclosed herewith as **Annexure-A**.

   Statement of Deviation or variation, pursuant to Regulation 32(1) of SEBI LODR Regulations for the quarter ended on September 30, 2026 is enclosed herewith as **Annexure- B**. Further, pursuant to Regulation 32(2) of SEBI LODR Regulations, the Company is not required to submit Statement of Deviation or variation from the forthcoming quarter, as hundred per cent (100%) proceeds of the Initial Public Offer has been fully utilized.

2. Mr. Sanjay Kumar, President – Operations, designated as Senior Management Personnel of the Company:

   On the recommendation of Nomination & Remuneration Committee, the Board of Directors has approved to designate Mr. Sanjay Kumar, President – Operations as Senior Management Personnel of the Company.

AKUMS
DRUGS & PHARMACEUTICALS LTD.
Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office)Delhi - 110083 (INDIA).
+91-11-69041000 CIN: L24239DL2004PLC125888
www.akums.in
akumsho@akums.net
+91-11-27023256

Details to be provided pursuant to SEBI LODR Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as **Annexure – C**.

The Board Meeting commenced at 02:33 P.M. (IST) and concluded at 04:23 P.M. (IST)

A copy of this disclosure is being updated on the website of the Company at www.akums.in

This is for your kind information and records.

Thanking You

Yours Faithfully

For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik
Digitally signed by Dharamvir Malik
Date: 2026.11.02 17:11:08 +05'30'

Dharamvir Malik
Company Secretary & Compliance Officer

Encl: As Above

Registered Office
304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).
+91-11-47511000 +91-11-27023256

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP
L 41, Connaught Circus,
Outer Circle,
New Delhi – 110 001
India

T +91 11 45002219
F +91 11 42787071

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Akums Drugs and Pharmaceuticals Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Company') for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above and the consideration of the review reports of the other auditor as referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

5. We draw attention to note 4 to the accompanying Statement regarding tax demand raised by the Income-tax authorities pursuant to a search and seizure operation carried out in earlier periods aggregating to ₹ 600.92 million for the block period from 01 April 2018 to 12 March 2025. The Company had filed an appeal under section 246A of the Income-Tax Act, 2025 before the Commissioner of Income-tax (Appeals). Basis legal assessment, the management is of the view that no adjustments are required in the accompanying Statement for such demand. Our conclusion is not modified in respect of this matter.

6. We did not review the interim financial results of Akums Employee Benefit Trust ("the Trust") included in the Statement, where such interim financial results reflects total assets of ₹ 3,007.00 million as at 30 September 2026, and total revenues of ₹ nil and ₹ nil, total net profit after tax of ₹ 8.26 million and ₹ 8.26 million, and total comprehensive income of ₹ 8.26 million and ₹ 8.26 million, for the quarter and six-month period ended on 30 September 2026, respectively, and net cash outflows of ₹ 0.08 million for the six-month period ended 30 September 2026, as considered in the statement. The Statement also includes the Company's share in the net profit (including other comprehensive income) of ₹ 8.73 million and ₹ 19.77 million for the quarter and six-month period ended on 30 September 2026, respectively, in respect of a Limited Liability Partnership ('LLP'), whose financial results have not been reviewed by us. Such interim financial results have been reviewed by the other auditor, whose reports have been furnished to us by the management, and our conclusion, in so far as it relates to the amounts and disclosures included in respect of the Trust and LLP, is based solely on the review reports of such other auditor.

   Further, the aforementioned financial results of the Trust and LLP have been prepared in conformity with the Accounting Standards specified under Section 133 of the Act read with the Companies (Accounting Standards) Rules, 2021 and other accounting principles generally accepted in India ('IGAAP'). The Company's management has converted the financial results of the Trust and LLP from IGAAP to accounting principles enunciated under Indian Accounting Standards specified under Section 133 of the Act and other accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Company's management. Our conclusion, in so far as it relates to the balances and affairs of the Trust and LLP, is based on the review reports of other auditor and the conversion adjustments prepared by the management of the Company and reviewed by us.

   Our conclusion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done by and the reports of the other auditor.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Anuj Yadav
Partner
Membership No.: 539888
UDIN: 26539888EGITNR2366

Place: New Delhi
Date: 02 November 2026

Akums Drugs and Pharmaceuticals Limited
Regd. Office: 304, Mohan Place, LSC, C-Block, Saraswati Vihar, Delhi-110034
CIN: L24239DL2004PLC125888
Email Id: cs@akums.net; Website: www.akums.in

Statement of unaudited standalone financial results for the quarter and six months period ended 30 September 2026

(₹ in million, unless otherwise stated)

S. No.	Particulars	Quarter ended			Six months period ended		Year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	**Income**						
	Revenue from operations	3,950.47	3,922.75	3,093.15	7,873.22	6,417.58	13,487.36
	Other income	257.97	261.04	270.77	519.01	556.32	1,129.65
	Total income (I)	**4,208.44**	**4,183.79**	**3,363.92**	**8,392.23**	**6,973.90**	**14,617.01**
II	**Expenses**						
	Cost of materials consumed	2,456.42	2,535.62	2,023.10	4,992.04	3,948.64	8,303.42
	Changes in inventories of finished goods and work-in-progress	(32.89)	(168.96)	(110.97)	(201.85)	(88.24)	(32.58)
	Employee benefits expense	651.57	589.18	545.77	1,240.75	1,053.16	2,179.93
	Finance costs	30.03	24.76	20.77	54.79	49.88	100.38
	Depreciation and amortisation expense	135.13	127.95	106.90	263.08	209.36	455.03
	Other expenses	529.70	481.88	466.34	1,011.58	894.03	2,061.99
	Total expenses (II)	**3,769.96**	**3,590.43**	**3,051.91**	**7,360.39**	**6,066.83**	**13,068.17**
III	**Profit before exceptional items and tax (I-II)**	**438.48**	**593.36**	**312.01**	**1,031.84**	**907.07**	**1,548.84**
IV	Exceptional items	-	-	-	-	-	65.19
V	**Profit before tax for the period/ year (III-IV)**	**438.48**	**593.36**	**312.01**	**1,031.84**	**907.07**	**1,483.65**
VI	**Tax expense**						
	Current tax						
	for current period/ year	117.77	153.50	83.13	271.27	245.36	377.93
	for earlier years	-	-	-	-	-	(13.92)
	Deferred tax (credit)/ charge						
	for current period/ year	(5.66)	(8.53)	(5.74)	(14.19)	(21.58)	(3.69)
	for earlier years	-	-	-	-	-	6.93
	Total tax expense	**112.11**	**144.97**	**77.39**	**257.08**	**223.78**	**367.25**
VII	**Profit for the period/ year (V-VI)**	**326.37**	**448.39**	**234.62**	**774.76**	**683.29**	**1,116.40**
VIII	**Other comprehensive income**						
	Items that will not be reclassified to statement of profit and loss						
	Re-measurement gains/(losses) on defined benefit plans	(17.82)	14.09	(21.30)	(3.73)	(8.62)	6.21
	Tax effect relating to these items	4.49	(3.55)	5.36	0.94	2.17	(1.56)
	Other comprehensive income, net of tax	**(13.33)**	**10.54**	**(15.94)**	**(2.79)**	**(6.45)**	**4.65**
IX	**Total comprehensive income for the period/ year (VII+VIII)** (comprising profit for the period/ year and other comprehensive income, net of tax)	**313.04**	**458.93**	**218.68**	**771.97**	**676.84**	**1,121.05**
X	Paid-up share capital (net off shares held by ESOP trust) (refer note 5)	306.21	306.21	306.21	306.21	306.21	306.21
XI	Other equity						23,969.46
XII	Earning per share (EPS) (face value of ₹ 2/- each) (in ₹)*						
	Basic and diluted	2.13	2.93	1.53	5.06	4.46	7.29

*EPS for the quarters and six months period have not been annualised

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Akums Drugs and Pharmaceuticals Ltd.

Akums Drugs and Pharmaceuticals Limited

CIN: L24239DL2004PLC125888

Unaudited standalone statement of assets and liabilities as at 30 September 2026

(₹ in million, unless otherwise stated)

Particulars	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited
ASSETS		
(1) Non-current assets		
(a) Property, plant and equipment	3,394.70	3,314.50
(b) Right-of-use assets	701.12	720.82
(c) Capital work-in-progress	809.42	515.67
(d) Investment property	179.08	181.13
(e) Intangible assets	50.39	33.96
(f) Intangible assets under development	-	6.60
(g) Financial assets		
(i) Investments	3,673.03	3,660.17
(ii) Loans	7,034.34	6,084.78
(iii) Others financial assets	108.50	91.38
(h) Non-current tax assets (net)	74.87	74.87
(i) Other non-current assets	126.80	205.93
Total non-current assets	**16,152.25**	**14,889.81**
(2) Current assets		
(a) Inventories	2,716.08	2,299.26
(b) Financial assets		
(i) Trade receivables	2,186.95	2,175.42
(ii) Cash and cash equivalents	396.27	463.84
(iii) Bank balances other than (ii) above	6,423.21	7,245.60
(iv) Others financial assets	34.51	232.63
(c) Other current assets	1,148.65	818.22
Total current assets	**12,905.67**	**13,234.97**
Total assets	**29,057.92**	**28,124.78**
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	306.21	306.21
(b) Other equity	24,282.12	23,969.46
Total equity	**24,588.33**	**24,275.67**
Liabilities		
(1) Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	430.03	439.29
(ii) Other financial liabilities	160.72	126.66
(b) Provisions	183.23	163.76
(c) Deferred tax liabilities (net)	64.31	79.45
Total non-current liabilities	**838.29**	**809.16**
(2) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	-	135.52
(ii) Lease liabilities	18.12	17.33
(iii) Trade payables		
Total outstanding dues to micro and small enterprises; and	347.18	287.14
Total outstanding dues of creditors other than micro and small enterprises	2,157.99	1,726.90
(iv) Other financial liabilities	765.22	632.44
(b) Other current liabilities	149.57	136.93
(c) Provisions	93.03	79.88
(d) Current tax liabilities (net)	100.19	23.81
Total current liabilities	**3,631.30**	**3,039.95**
Total equity and liabilities	**29,057.92**	**28,124.78**

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Akums Drugs and Pharmaceuticals Ltd.

Akums Drugs and Pharmaceuticals Limited

CIN: L24239DL2004PLC125888

Unaudited standalone statement of cash flow for the six months period ended 30 September 2026

(₹ in million, unless otherwise stated)

Particulars		Six months period ended	
		30 September 2026	30 September 2025
		Unaudited	Unaudited
A. Cash flow from operating activities			
Net profit before tax		**1,031.84**	**907.07**
Adjustments for:			
Depreciation and amortisation expense		263.08	209.36
(Reversal of)/ provision for expected credit loss on trade receivable		(22.33)	45.71
Provision on advance to suppliers		20.08	-
Loss/ (profit) on sale of property, plant and equipment (net)		2.03	(0.45)
Finance costs		54.79	49.88
Interest income		(469.35)	(503.24)
Gain on reassessment of right-of-use assets		-	(0.06)
Liability no longer required written back		(0.85)	(0.04)
Share of profit from investment in Limited Liability Partnership (LLP)		(19.77)	(18.82)
Rental income		(17.59)	(20.59)
Unrealised foreign exchange differences (net)		1.60	(3.49)
Operating profit before working capital changes		**843.53**	**665.33**
Adjustments for movement in working capital changes:			
Increase in inventories		(416.82)	(47.72)
Decrease in trade receivables		10.80	15.77
Decrease in other financial assets		28.10	11.46
Increase in other assets		(338.38)	(95.69)
Increase/ (decrease) in trade payables		490.38	(113.44)
Increase/ (decrease) in other financial liabilities		127.83	(193.77)
Increase in provisions		28.89	15.11
Increase/ (decrease) in other liabilities		12.64	(3.31)
Cash flow generated from operations		**786.97**	**253.74**
Less: Income tax paid (net)		(194.89)	(145.36)
Net cash flow generated from operating activities	**(A)**	**592.08**	**108.38**
B. Cash flow from investing activities			
Purchase of property, plant and equipment and intangible assets (including investment property, capital work-in-progress, capital advances and payable towards property, plant and equipment)		(528.44)	(620.97)
Proceeds from sale of property plant and equipment		7.23	7.65
Investment in subsidiaries		(12.86)	-
Investment in deposits having original maturity of more than 3 months (net)		667.10	(4,976.31)
Loan given to subsidiary companies / LLP		(5,248.70)	(4,018.21)
Loan repaid by subsidiary companies / LLP		4,308.50	9,087.82
Withdrawals from partnership firm		173.16	-
Interest received		614.79	535.90
Rent received		17.59	20.59
Net cash flow (used in)/ generated from investing activities	**(B)**	**(1.63)**	**36.47**
C. Cash flow from financing activities			
Repayment of current borrowings (net)		(135.52)	(1.30)
Payment of principal components of lease liabilities		(8.47)	(18.25)
Payment of interest components of lease liabilities		(20.40)	(18.91)
Interest paid		(34.39)	(30.97)
Dividend paid (refer note 6)		(459.24)	-
Net cash flow used in financing activities	**(C)**	**(658.02)**	**(69.43)**
Net (decrease)/ increase in cash and cash equivalents	**(A+B+C)**	**(67.57)**	**75.42**
Cash and cash equivalents at the beginning of the period		463.84	764.92
Cash and cash equivalents at the end of the period		**396.27**	**840.34**

The above unaudited standalone statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7 - Statement of Cash Flows.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Akums Drugs and Pharmaceuticals Ltd.

Notes to the unaudited standalone financial results for the quarter and six months period ended 30 September 2026:

1 The above standalone financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on 2 November 2026. These standalone financial results for the quarter and six months period ended 30 September 2026 have been subjected to limited review by statutory auditor and they have issued an unmodified report on the aforementioned results.

2 These standalone financial results of Akums Drugs and Pharmaceuticals Limited (the 'Company') have been prepared in accordance with the recognition and measurement principles as laid down in the Indian Accounting Standards 34, Interim Financial Reporting ('Ind AS - 34'), prescribed under Section 133 of the Companies Act, 2013 (the 'Act') and other accounting principles generally accepted in India and are in compliance with the presentation and disclosure requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

3 The Company operates in only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segment is not applicable and accordingly not made.

4 During the financial year ended 31 March 2025, from 15 January 2025 to 21 January 2025, the Income Tax Department ('IT Department') conducted a search and seizure operation under Section 132 of the Income Tax Act, 1961 ('Tax Act'), at certain offices and manufacturing units of the Company and its subsidiaries, and the residences of selected key managerial personnel of the Company and its subsidiaries. During the search and seizure proceedings, the Company fully cooperated, provided the required information and responses to the IT Department. As a part of search and seizure operation, the IT Department cloned electronic books of accounts, laptops, data backups and seized certain documents, cash and other materials for further investigation. The business and operations of the Company continued without any disruptions, except some minor operational hiccups, and customer commitments were met during this period.

Following the search, the Company received various notices and communications including show cause notices issued by the IT Department in connection with the ongoing block assessment proceedings under Sections 158BC, 142(1) and 143(2) of the Tax Act. The Company has furnished the requisite returns, information, documents and responses sought by the authorities from time to time, including responses to show cause notices issued.

During the previous quarter ended 30 June 2026, the IT Department passed an assessment order u/s 158BC of the Tax Act and raised tax demand of ₹ 600.92 million in respect of the disallowance of certain expenses, additions on account of undisclosed income for the aforesaid block period, against which the management filed an appeal under section 246A of the Tax Act before the Commissioner of Income-tax (Appeals). During the quarter ended 30 September 2026, the Company has deposited ₹ 9 million as advance under protest. Subsequent to the quarter end, the Company has further deposited ₹ 16.20 million under protest towards the said demand.

Based on the facts and circumstances of the case, including the assessment order and appeal filed by the Company, report of external fact finding review conducted by the management expert and the legal opinion obtained by the management in respect of the matters under dispute, the management is of the view that no adjustments are required to these standalone financial results for the quarter and six months period ended 30 September 2026 in this regard.

5 The Akums Employee Benefits Trust ("ESOP Trust") has been treated as an extension of the Company and accordingly, shares held by ESOP Trust are netted off from the paid up share capital and calculation of earnings per share (basic and diluted) have been done accordingly. Further, all the assets, liabilities, income and expenses of the ESOP Trust are accounted for as assets, liabilities, income and expenses of the Company.

6 The shareholders of the Company at the Annual General Meeting held on 10 July 2026 approved the final dividend of ₹ 1 per equity share and special dividend of ₹ 2 per equity share (aggregate ₹ 3 per equity share) for the financial year ended 31 March 2026, as recommended by the Board of Directors on 14 May 2026. Out of the total dividend liability of ₹ 472.18 million, an amount of ₹ 472.12 million has been paid during the quarter ended 30 September 2026, including ₹ 12.88 million paid to ESOP Trust, being an extension of the Company. The remaining amount of ₹ 0.06 million is unclaimed, and the Company is taking take due efforts to pay the same to the respective shareholders.

For and on behalf of Board of Directors of
Akums Drugs and Pharmaceuticals Limited

Sanjeev Jain
Managing Director
DIN: 00323433

Place: New Delhi
Date: 2 November 2026

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Akums Drugs and Pharmaceuticals Ltd.

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP
L 41, Connaught Circus,
Outer Circle,
New Delhi – 110 001
India

T +91 11 45002219
F +91 11 42787071

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Akums Drugs and Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw attention to note 6 to the accompanying Statement regarding tax demand raised by the Income-tax authorities pursuant to a search and seizure operation carried out in earlier periods aggregating to ₹ 1,560.18 million for the block period from 01 April 2018 to 12 March 2025. The Holding Company and the respective subsidiaries had filed an appeal under section 246A of the Income-Tax Act, 2025 before the Commissioner of Income-tax (Appeals). Basis legal assessment, the management of the Holding Company is of the view that no adjustment is required in the accompanying Statement for such demand. Our conclusion is not modified in respect of this matter.

6. We did not review the interim financial results of 6 subsidiaries included in the Statement, whose financial results reflects total assets of ₹ 2,308.39 million as at 30 September 2026, and total revenues of ₹ 390.59 million and ₹ 727.57 million, total net profit/(loss) after tax of ₹ 2.77 million and ₹ (1.63) million, total comprehensive income of ₹ 1.72 million and ₹ 0.62 million, for the quarter and six-month period ended on 30 September 2026, respectively, and net cash outflows of ₹ 830.87 million for the six-month period ended 30 September 2026, as considered in the Statement. These interim financial results have been reviewed by other auditor whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the review reports of such other auditor and the procedures performed by us as stated in paragraph 3 above.

   Further, of these subsidiaries, 1 subsidiary being LLP, whose interim financial results have been prepared in accordance with the Accounting Standards specified under Section 133 of the Act read with the Companies (Accounting Standards) Rules, 2021 and other accounting principles generally accepted in India ('IGAAP'). The Holding Company's management has converted the financial results of such subsidiary from IGAAP to accounting principles enunciated under Indian Accounting Standards specified under Section 133 of the Act and other accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of such subsidiary are based on the report of other auditor and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

   Our conclusion is not modified in respect of these matters with respect to our reliance on the work done by and the reports of the other auditor.



Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

7. The Statement includes the interim financial information of 3 subsidiaries, which have not been reviewed by their auditors, whose interim financial information reflects total assets of ₹ 20.81 million as at 30 September 2026, and total revenues of ₹ nil and ₹ nil, net loss after tax of ₹ 2.17 million and ₹ 2.67 million, total comprehensive loss of ₹ 2.66 million and ₹ 3.15 million for the quarter and six-month period ended 30 September 2026 respectively, and net cash inflows of ₹ 12.83 million for the six-month period ended 30 September 2026 as considered in the Statement and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

   Our conclusion is not modified in respect of this matter with respect to our reliance on the financial information certified by the Board of Directors.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Anuj Yadav
Partner
Membership No. 539888
UDIN: 26539888YFMHRH2457

Place: New Delhi
Date: 02 November 2026

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)

Annexure 1

List of subsidiaries included in the Statement

1. Pure and Cure Healthcare Private Limited
2. Malik Lifesciences Private Limited
3. Maxcure Nutravedics Limited
4. Unosource Pharma Limited
5. Akumentis Healthcare Limited
6. Akums Healthcare Limited
7. Sarvagunaushdhi Private Limited
8. Plenteous Pharmaceuticals Limited
9. Upadhrish Researchem LLP
10. Nicholas Healthcare Limited
11. Qualymed Pharma Private Limited
12. Akums Healthcare UK Limited
13. Akums Healthcare Zambia Private Limited (w.e.f. 13 October 2025)
14. Akums Healthcare Malta Private Limited (w.e.f. 20 October 2025)
15. Medibox Pharma Private Limited (subsidiary of Maxcure Nutravedics Limited)



Akums Drugs and Pharmaceuticals Limited
Regd. Office: 304, Mohan Place, LSC, C-Block, Saraswati Vihar, Delhi-110034
CIN: L24239DL2004PLC125888
Email Id: cs@akums.net; Website: www.akums.in
Statement of unaudited consolidated financial results for the quarter and six months period ended 30 September 2026

(₹ in million, unless otherwise stated)

S. No.	Particulars	Quarter ended			Six months period ended		Year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	**Income**						
	Revenue from operations	13,423.87	11,666.29	10,175.30	25,090.16	20,415.62	43,590.17
	Other income	289.06	303.80	323.65	592.86	590.96	1,287.25
	Total income (I)	**13,712.93**	**11,970.09**	**10,498.95**	**25,683.02**	**21,006.58**	**44,877.42**
II	**Expenses**						
	Cost of materials consumed	7,194.57	6,821.24	5,526.26	14,015.81	11,005.22	22,986.83
	Purchase of stock-in-trade	505.18	264.88	567.06	770.06	777.85	2,009.97
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(32.64)	(631.89)	(167.69)	(664.53)	(38.28)	138.38
	Employee benefits expense	2,242.72	2,014.33	1,892.70	4,257.05	3,654.13	7,538.24
	Finance costs (refer note 4)	256.78	247.56	233.04	504.34	464.39	940.73
	Depreciation and amortisation expense	432.12	410.65	378.64	842.77	747.84	1,545.51
	Other expenses	1,566.76	1,450.95	1,412.21	3,017.71	2,782.24	5,696.51
	Total expenses (II)	**12,165.49**	**10,577.72**	**9,842.22**	**22,743.21**	**19,393.39**	**40,856.17**
III	**Profit before exceptional items and tax (I-II)**	**1,547.44**	**1,392.37**	**656.73**	**2,939.81**	**1,613.19**	**4,021.25**
IV	Exceptional items	-	-	-	-	-	200.24
V	**Profit before tax for the period/ year (III-IV)**	**1,547.44**	**1,392.37**	**656.73**	**2,939.81**	**1,613.19**	**3,821.01**
VI	**Tax expense**						
	Current tax						
	for current period/ year	254.77	271.50	191.35	526.27	435.75	905.75
	for earlier years	-	-	-	-	-	(7.48)
	Deferred tax charge/ (credit)						
	for current period/ year	147.02	111.09	38.42	258.11	103.63	345.52
	for earlier years	-	-	-	-	-	13.25
	Total tax expense	**401.79**	**382.59**	**229.77**	**784.38**	**539.38**	**1,257.04**
VII	**Profit for the period/ year (V-VI)**	**1,145.65**	**1,009.78**	**426.96**	**2,155.43**	**1,073.81**	**2,563.97**
VIII	**Other comprehensive income**						
	(a) Items that will not be reclassified to profit and loss						
	Remeasurements of defined benefit plans	(47.63)	39.09	(53.72)	(8.54)	(30.75)	13.16
	Income tax relating to above mentioned items	10.88	(7.98)	10.69	2.90	5.12	(3.90)
	(b) Items that will be reclassified to profit and loss						
	Exchange differences on translation of foreign operations	(0.49)	0.01	-	(0.48)	-	(0.03)
	Other comprehensive income, net of tax	**(37.24)**	**31.12**	**(43.03)**	**(6.12)**	**(25.63)**	**9.23**
IX	**Total comprehensive income for the period/ year (VII+VIII)** (comprising profit for the period/ year and other comprehensive income, net of tax)	**1,108.41**	**1,040.90**	**383.93**	**2,149.31**	**1,048.18**	**2,573.20**
X	**Profit for the period/ year attributable to:**						
	Owners of the Parent	1,128.51	1,000.10	407.83	2,128.61	1,042.58	2,551.88
	Non controlling interest	17.14	9.68	19.13	26.82	31.23	12.09
XI	**Other comprehensive income for the period/ year attributable to:**						
	Owners of the Parent	(37.00)	31.20	(42.95)	(5.80)	(25.32)	9.56
	Non controlling interest	(0.24)	(0.08)	(0.08)	(0.32)	(0.31)	(0.33)
XII	**Total comprehensive income for the period/ year attributable to:**						
	Owners of the Parent	1,091.51	1,031.30	364.88	2,122.81	1,017.26	2,561.44
	Non controlling interest	16.90	9.60	19.05	26.50	30.92	11.76
XIII	Paid-up share capital (net off shares held by ESOP trust) (refer note 3)	306.21	306.21	306.21	306.21	306.21	306.21
XIV	Other equity						32,827.27
XV	Earning per share (EPS) (face value of ₹ 2/- each) (in ₹)*	7.37	6.53	2.66	13.90	6.81	16.67
	Basic and diluted						

*EPS for the quarters and six months period ended have not been annualised

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Akums Drugs and Pharmaceuticals Ltd.

UNAUDITED CONSOLIDATED SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

The Group is engaged in five business segments a) Contract Development and Manufacturing operations (CDMO); b) Active Pharmaceutical Ingredient (API); c) Domestic Branded Formulations; d) International Branded Formulations and e) Trade Generics. Disclosures as per Indian Accounting Standard (Ind AS-108) "Operating Segment" has been disclosed herewith :

(₹ in million, unless otherwise stated)

Particulars	Quarter ended			Six months period ended		Year ended
	30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations (including inter-segment)						
a) CDMO	11,687.09	10,143.64	8,526.66	21,830.73	17,178.40	37,101.90
b) API	409.32	455.53	508.99	864.85	1,098.10	2,313.94
c) Domestic branded formulations	1,319.20	1,152.79	1,219.40	2,471.99	2,294.06	4,463.04
d) International branded formulations	437.79	345.48	224.31	783.27	574.95	1,434.62
e) Trade generics	230.51	209.46	245.12	439.97	480.58	1,003.27
	14,083.91	**12,306.90**	**10,724.48**	**26,390.81**	**21,626.09**	**46,316.77**
II. Revenue from operations (external customers)						
a) CDMO	11,148.66	9,642.12	8,043.29	20,790.78	16,176.65	34,851.99
b) API	287.71	316.46	444.60	604.17	894.93	1,844.35
c) Domestic branded formulations	1,319.20	1,152.79	1,219.40	2,471.99	2,294.06	4,463.04
d) International branded formulations	437.79	345.48	224.31	783.27	574.95	1,434.62
e) Trade generics	230.51	209.44	243.70	439.95	475.03	996.17
Revenue from operations	**13,423.87**	**11,666.29**	**10,175.30**	**25,090.16**	**20,415.62**	**43,590.17**
III. Segment results before depreciation*						
a) CDMO	1,682.43	1,634.49	843.10	3,316.92	2,037.72	4,669.31
b) API	(57.41)	(39.03)	(140.31)	(96.44)	(203.62)	(400.96)
c) Domestic branded formulations	240.37	118.28	263.87	358.65	422.34	898.00
d) International branded formulations	99.07	68.91	54.88	167.98	135.36	364.99
e) Trade generics	11.85	1.40	(28.73)	13.25	(83.48)	(101.20)
IV. Segment results**						
a) CDMO	1,294.26	1,265.28	505.91	2,559.54	1,371.00	3,290.31
b) API	(101.44)	(81.46)	(184.14)	(182.90)	(290.65)	(576.55)
c) Domestic branded formulations	230.01	108.34	258.82	338.35	412.16	872.38
d) International branded formulations	91.60	62.15	49.78	153.75	126.20	342.31
e) Trade generics	11.30	0.12	(32.54)	11.42	(91.19)	(113.93)
Sub total	**1,525.73**	**1,354.43**	**597.83**	**2,880.16**	**1,527.52**	**3,814.52**
Unallocated corporate income/ (expenses) [net]	8.37	7.00	2.10	15.37	4.20	6.40
Interest income	251.38	259.50	273.49	510.88	512.88	1,071.12
Finance costs	(238.04)	(228.56)	(216.69)	(466.60)	(431.41)	(870.79)
Profit before exceptional items and tax	**1,547.44**	**1,392.37**	**656.73**	**2,939.81**	**1,613.19**	**4,021.25**
Exceptional items	-	-	-	-	-	200.24
Profit before tax	**1,547.44**	**1,392.37**	**656.73**	**2,939.81**	**1,613.19**	**3,821.01**
Tax expenses	401.79	382.59	229.77	784.38	539.38	1,257.04
Profit for the period/ year	**1,145.65**	**1,009.78**	**426.96**	**2,155.43**	**1,073.81**	**2,563.97**
V. Segment assets						
a) CDMO	34,645.88	33,181.93	28,118.25	34,645.88	28,118.25	30,544.04
b) API	3,748.03	3,739.55	4,052.36	3,748.03	4,052.36	3,969.46
c) Domestic branded formulations	961.30	923.10	781.99	961.30	781.99	770.47
d) International branded formulations	912.42	936.49	796.13	912.42	796.13	929.42
e) Trade generics	466.40	414.59	535.82	466.40	535.82	456.76
Less :- Inter-segment eliminations	(736.61)	(875.48)	(639.99)	(736.61)	(639.99)	(916.92)
Segment assets	**39,997.42**	**38,320.18**	**33,644.56**	**39,997.42**	**33,644.56**	**35,753.23**
Un-allocated corporate assets	18,318.29	18,715.22	17,948.37	18,318.29	17,948.37	18,716.42
Total assets	**58,315.71**	**57,035.40**	**51,592.93**	**58,315.71**	**51,592.93**	**54,469.65**
VI. Segment liabilities						
a) CDMO	19,867.71	19,389.52	17,289.63	19,867.71	17,289.63	18,177.11
b) API	490.41	446.58	435.43	490.41	435.43	313.04
c) Domestic branded formulations	1,288.90	1,313.06	1,118.54	1,288.90	1,118.54	1,146.10
d) International branded formulations	593.70	541.20	458.22	593.70	458.22	584.24
e) Trade generics	339.07	375.48	411.51	339.07	411.51	437.71
Less :- Inter-segment elimnations	(736.61)	(875.48)	(639.99)	(736.61)	(639.99)	(916.92)
Segment liabilities	**21,843.18**	**21,190.36**	**19,073.34**	**21,843.18**	**19,073.34**	**19,741.28**
Un-allocated corporate liabilities	1,239.63	1,492.93	835.30	1,239.63	835.30	1,417.16
Total liabilities	**23,082.81**	**22,683.29**	**19,908.64**	**23,082.81**	**19,908.64**	**21,158.44**

* Segment results before depreciation are computed by aggregating profit/ (loss) before tax, exceptional items, finance costs, and depreciation and amortisation expense, and deducting interest income and other unallocated income/ (expenses) [net].

** Segment results is calculated as segment results before depreciation less finance costs pertaining to segments and depreciation and amortisation expense.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Akums Drugs and Pharmaceuticals Ltd.

Akums Drugs and Pharmaceuticals Limited
CIN: L24239DL2004PLC125888
Statement of unaudited consolidated statement of assets and liabilities as at 30 September 2026

(₹ in million, unless otherwise stated)

Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
ASSETS		
(1) Non-current assets		
(a) Property, plant and equipment	13,342.77	12,794.08
(b) Right-of-use assets	1,887.83	1,688.50
(c) Capital work-in-progress	2,459.02	1,766.64
(d) Goodwill	20.63	20.63
(e) Other intangible assets	104.69	54.82
(f) Intangible assets under development	1.12	7.27
(g) Financial assets		
(i) Investments	1.43	1.43
(ii) Other financial assets	306.67	293.27
(h) Non-current tax assets (net)	157.59	179.51
(i) Deferred tax assets	1,338.99	1,708.88
(j) Other non-current assets	436.13	356.04
Total non-current assets	**20,056.87**	**18,871.07**
(2) Current assets		
(a) Inventories	9,034.81	7,557.13
(b) Financial assets		
(i) Investments	708.54	-
(ii) Trade receivables	8,594.58	7,965.64
(iii) Cash and cash equivalents	1,835.93	3,860.05
(iv) Bank balances other than (ii) above	14,255.19	12,945.93
(v) Other financial assets	265.01	295.71
(c) Other current assets	3,564.78	2,974.12
Total current assets	**38,258.84**	**35,598.58**
Total assets	**58,315.71**	**54,469.65**
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	306.21	306.21
(b) Other equity	34,722.46	32,827.27
Equity attributable to equity holders of the Parent	35,028.67	33,133.48
(c) Non-controlling interest	204.23	177.73
Total equity	**35,232.90**	**33,311.21**
LIABILITIES		
(1) Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	732.89	768.44
(ii) Other financial liabilities	427.46	371.24
(b) Provisions	554.39	486.07
(c) Deferred tax liabilities	127.72	177.06
(d) Other non current liabilities	8,584.53	8,408.06
Total non-current liabilities	**10,426.99**	**10,210.87**
(2) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	361.53	729.54
(ii) Lease liabilities	76.19	76.33
(iii) Trade payables		
Total outstanding dues to micro and small enterprises; and	1,139.81	879.75
Total outstanding dues of creditors other than micro and small enterprises	6,502.39	5,141.83
(iv) Other financial liabilities	1,638.27	1,336.48
(b) Other current liabilities	2,064.29	2,040.18
(c) Provisions	709.44	654.21
(d) Current tax liabilities (net)	163.90	89.25
Total current liabilities	**12,655.82**	**10,947.57**
Total equity and liabilities	**58,315.71**	**54,469.65**

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Akums Drugs and Pharmaceuticals Ltd.

Akums Drugs and Pharmaceuticals Limited

CIN: L24239DL2004PLC125888

Statement of unaudited consolidated cash flow statement for six months period ended 30 September 2026

(₹ in million, unless otherwise stated)

Particulars		Six months period ended	
		30 September 2026	30 September 2025
		Unaudited	Unaudited
A. Cash flow from operating activities			
Net profit before tax		**2,939.81**	**1,613.19**
Add/ less: non-cash adjustments			
Depreciation and amortisation expense		842.77	747.84
Bad debts		0.12	0.19
(Reversal of)/ provision for expected credit loss on trade receivable		(20.51)	126.25
Provision on advance to suppliers		20.10	-
Liabilities no longer required, written back		(5.63)	(1.51)
Unrealized foreign exchange differences (net)		10.08	-
Loss/ (profit) on sale of property, plant and equipment (net)		9.94	(0.99)
Finance costs		504.34	464.39
Gain on reassessment of right-of-use assets		(0.58)	(0.35)
Profit on sale of current investments		(2.65)	-
Interest income		(522.47)	(521.29)
Operating profit before working capital changes		**3,775.32**	**2,427.72**
Adjustments for working capital changes			
(Increase)/decrease in inventories		(1,334.75)	325.74
(Increase)/decrease in trade receivables		(628.02)	114.26
(Increase)/decrease in other assets		(637.99)	19.05
Increase/(decrease) in trade payables		1,613.86	(325.48)
Increase/(decrease) in other financial liabilities		300.00	(273.21)
Increase in provisions		100.57	34.57
(Decrease)/increase in other liabilities		(202.11)	9,510.85
Cash flow generated from operations (gross)		**2,986.88**	**11,833.50**
Less: Income tax paid (net)		(429.63)	(311.43)
Net cash flow generated from operating activities	**(A)**	**2,557.25**	**11,522.07**
B. Cash flow from investing activities			
Purchase of property, plant and equipment and intangible assets (including capital work-in-progress, capital advances and payable towards property, plant and equipment)		(1,542.07)	(1,120.45)
Proceeds from sale of property, plant and equipment		47.15	41.22
Acquisition on account of business combination (refer note 5)		(560.00)	-
Investment in deposits having original maturity of more than 3 months, (net)		(889.41)	(9,278.36)
Investment in bonds, commercial paper and other short term investments		(494.40)	-
Investment in mutual funds		(202.02)	-
Interest received		99.46	292.27
Net cash flow used in investing activities	**(B)**	**(3,541.29)**	**(10,065.32)**
C. Cash flow from financing activities			
Proceeds/ (repayment of) from current borrowings (net)		(368.01)	(38.10)
Payment of principal components of lease liabilities		(109.85)	(56.83)
Payment of interest components of lease liabilities		(37.43)	(32.51)
Interest paid		(65.55)	(50.24)
Dividend paid (refer note 7)		(459.24)	-
Net cash flow used in financing activities	**(C)**	**(1,040.08)**	**(177.68)**
Net (decrease)/ increase in cash and cash equivalents	**(A+B+C)**	**(2,024.12)**	**1,279.07**
Cash and cash equivalents as at the beginning of the period		3,860.05	1,011.91
Cash and cash equivalents as at the end of the period		**1,835.93**	**2,290.98**

Note: The above unaudited consolidated statement of cash flows has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7 - Statement of Cash Flows.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Akums Drugs and Pharmaceuticals Ltd.

Notes to the unaudited consolidated financial result for the quarter and six months period ended 30 September 2026:

1 The above consolidated financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on 2 November 2026. These consolidated financial results for the quarter and six months period ended 30 September 2026 have been subjected to limited review by statutory auditor and they have issued an unmodified report on the aforementioned results.

2 These consolidated financial results of Akums Drugs and Pharmaceuticals Limited (the 'Holding Company' or 'Parent'), together with its subsidiaries (collectively the 'Group') have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards 34, Interim Financial Reporting ('Ind AS - 34'), prescribed under Section 133 of the Companies Act, 2013 (the 'Act') and other accounting principles generally accepted in India and are in compliance with the presentation and disclosure requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

3 The Akums Employee Benefit Trust ("ESOP Trust") has been treated as an extension of the Holding Company and accordingly, shares held by ESOP Trust are netted off from the paid up share capital and calculation of earnings per share (basic and diluted) have been done accordingly. Further, all the assets, liabilities, income and expenses of the trust are accounted for as assets, liabilities, income and expenses of the Holding Company.

4 Finance costs for the quarter ended 30 September 2026 include ₹202.15 million (30 June 2026: ₹200.54 million; 30 September 2025: ₹199.00 million) and for the six months period ended 30 September 2026 include ₹402.69 million (30 September 2025: ₹381.64 million), representing the unwinding of the significant financing component in a long-term advance received from a customer. This has been accounted for in accordance with Ind AS 115, Revenue from Contracts with Customers.

The related tax effect of this unwinding has been recognised as deferred tax charge of ₹50.88 million for the quarter ended 30 September 2026 (30 June 2026: ₹50.47 million; 30 September 2025: ₹50.08 million) and ₹101.35 million for the six months period ended 30 September 2026 (30 September 2025: ₹96.05 million).

5 During the quarter ended 30 September 2026, Pure and Cure Healthcare Private Limited, a wholly-owned subsidiary of the Parent, completed the acquisition of the manufacturing business of Oriflame India Private Limited, comprising manufacturing facilities at Roorkee and Noida along with a leased warehouse, for a total cash consideration of ₹560.00 million. The acquisition is expected to strengthen the Group's manufacturing capacity and expand its presence in the color cosmetics, skincare and wellness segments.

The acquisition has been accounted for as a business combination under the acquisition method in accordance with Ind AS 103, Business Combinations. The identifiable assets acquired and liabilities assumed have been recognised at their acquisition date fair values basis the purchase price allocation assessment obtained by the management. The fair values of such net identifiable assets acquired exceed the consideration transferred by ₹231.69 million (net of deferred tax assets/ liability) which has been recognised as Capital Reserve within other equity in accordance with Ind AS 103 in these consolidated financial results.

6 During the financial year ended 31 March 2025, from 15 January 2025 to 21 January 2025, the Income Tax Department ('IT Department') conducted a search and seizure operation under Section 132 of the Income Tax Act, 1961 ('Tax Act'), at certain offices and manufacturing units of the Holding Company and its subsidiaries, and the residences of select key managerial personnel of the Group. During the search and seizure proceedings, the Group fully cooperated, provided the required information and responses to the IT Department. As a part of search and seizure operation, the IT Department cloned electronic books of accounts, laptops, data backups and seized certain documents, cash and other materials for further investigation. The business and operations of the Group continued without any disruptions, except some minor operational hiccups, and customer commitments were met during this period.
Following the search, the Group received various notices and communications including show cause notices issued by IT Department in connection with the ongoing block assessment proceedings under Sections 158BC, 142(1) and 143(2) of the Tax Act. The Group furnished the requisite returns, information, documents and responses sought by the authorities from time to time, including responses to show cause notices issued.

During the previous quarter ended 30 June 2026, the IT Department passed an assessment order u/s 158BC of the Tax Act and raising tax demand of ₹ 1,560.18 million in respect of the disallowance of certain expenses, additions on account of undisclosed income for the aforesaid block period, against which the Group had filed an appeal under section 246A of the Tax Act before the Commissioner of Income-tax (Appeals). During the quarter ended 30 September 2026, the Group has deposited ₹ 70.54 million as advance under protest. Subsequent to quarter end, Group has further deposited ₹ 39.20 million under protest towards the said demand. Accordingly, the total amount deposited under protest against the aforesaid demand amounts to ₹ 109.74 million.

Based on the facts and circumstances of the case, including the assessment order and appeals filed by the Group, report of external fact finding review conducted by the management expert and the legal opinion obtained by the management in respect of the matters under dispute, the management is of the view that no material adjustments are required to these consolidated financial results for the quarter or six months period ended 30 September 2026 in this regard.

7 The shareholders of the Holding Company at the Annual General Meeting held on 10 July 2026 approved the final dividend of ₹ 1 per equity share and special dividend of ₹ 2 per equity share (aggregate ₹ 3 per equity share) for the financial year ended 31 March 2026, as recommended by the Board of Directors on 14 May 2026. Out of the total dividend liability of ₹ 472.18 million, an amount of ₹ 472.12 million has been paid during the quarter ended 30 September 2026, including ₹ 12.88 million paid to Akums Employee Benefits Trust ("ESOP Trust"), being an extended arm of the Holding Company. The remaining amount of ₹ 0.06 million is unclaimed, and the Holding Company is taking due efforts to pay the same to the respective shareholders.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Akums Drugs and Pharmaceuticals Ltd.

For and on behalf of Board of Directors of
Akums Drugs and Pharmaceuticals Limited

Sanjeev Jain
Managing Director
DIN: 00223433

Place: New Delhi
Date: 2 November 2026

Annexure - B

AKUMS
DRUGS & PHARMACEUTICALS LTD.

Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, (Adjoining CBSE Office) Delhi - 110083 (INDIA).
+91-11-69041000 CIN: L24239DL2004PLC125888
www.akums.in
akumsho@akums.net
+91-11-27023256

Statement of Deviation / Variation in utilisation of funds Raised	
Name of listed entity	Akums Drugs and Pharmaceuticals Limited
Mode of Fund Raising	Public Issues
Date of Raising Funds	August 2, 2024 (Listed on August 6, 2024 on BSE Limited and National Stock Exchange of India Limited)
Amount Raised	6800.00 million
Report filed for Quarter ended	30-09-2026
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	CRISIL Ratings Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified Object, if any	Original Allocation**	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
Repayment/ prepayment of indebtedness of the Company	Not Applicable	1,599.10	0	1,599.10	No deviation/variation in utilization of funds raised through IPO	-
Repayment/ prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	Not Applicable	2,270.90	0	2,270.90		-
Funding incremental working capital requirements of our Company	Not Applicable	550.00	0	550.00		-
Pursuing inorganic growth initiatives through acquisitions	Not Applicable	278.70	301.80***	301.80		-
General corporate purposes (GCP)*	Not Applicable	1,675.00	1,700.00***	1,700.00		-

Registered Office
304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).
+91-11-47511000 +91-11-27023256

AKUMS
DRUGS & PHARMACEUTICALS LTD.

Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).
+91-11-69041000 CIN: L24239DL2004PLC125888
www.akums.in
akumsho@akums.net
+91-11-27023256

*The amount utilized for general corporate purposes does not exceed 25% of the Gross Proceeds (amounting to Rs 1700.00 million) from the Fresh Issue.

** The amount of original allocation represents the amount raised through fresh Issue net of offer expenses as mentioned in the prospectus dated August 1, 2024.

***During the quarter ended March 31, 2026, unutilised issue expenses of Rs 48.10 million has been allocated towards the object of - "GCP" by Rs 25 million & "Pursuing inorganic growth initiatives through acquisitions" by Rs 23.10 million as actual utilization towards issue expenses is lower than the proposed deployment resulting in an increase in net proceeds. The allocation of proceeds was duly approved by the Board of Directors of the Company through a resolution dated 13th February 2026.

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc

Akums Drugs & Pharmaceuticals Limited

Sumeet Sood
Chief Financial Officer

Date: 02.11.2026
Place: Delhi

Registered Office
304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).
+91-11-47511000 +91-11-27023256

Annexure – C

Details under amended Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular vide No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Particulars	Details
1.	reason for change viz. appointment, ~~re-appointment, resignation, removal, death or otherwise;~~	Mr. Sanjay Kumar, President – Operations of the Company is designated as Senior Management Personnel
2.	date of appointment/~~re-appointment/cessation (as applicable)~~ & term of appointment/~~re-appointment;~~	Date of Appointment: w.e.f. November 02, 2026 Term of Appointment: Full-time employment, as per the policy of the Company
3.	brief profile (in case of appointment);	Mr. Sanjay Kumar has a vast experience of 27 years in manufacturing and managing operations of various Pharma Companies and has previously associated with various companies including Cadila Pharmaceuticals Limited, Zydus Lifesciences Limited, IPCA Laboratories Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Ranbaxy Laboratories Limited, Fresenius Kabi India Private Limited (Dabur Pharma) and Cipla Limited
4.	disclosure of relationships between directors (in case of appointment of a director).	Not Applicable